MiR-125b regulation of androgen receptor signaling via modulation of the receptor complex co-repressor NCOR2

BioResearch Open Access

Volumn 1, Issue 2, 2012, Pages 55-62

  Yang, Xiaoping ^a   Bemis, Lynne ^a,b   Su, Lih Jen ^a   Gao, Dexiang ^c,d   Flaig, Thomas W ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MINNESOTA DULUTH   (United States)

^c Children's Hospital Colorado   (United States)

^d Global Health and Health Disparities   (United States)

Author keywords

Androgen receptor complex; Apoptosis; Castration; Circulating micro RNA; Prostate cancer

Indexed keywords

ANDROGEN RECEPTOR; BICALUTAMIDE; LUCIFERASE; MICRORNA 125B; SILENCING MEDIATOR OF RETINOID AND THYROID HORMONE RECEPTOR;

3' UNTRANSLATED REGION; ANDROGEN DEPRIVATION THERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BINDING ASSAY; CANCER CELL; CANCER CELL CULTURE; CANCER GROWTH; CASTRATION; COMPLEX FORMATION; CONTROLLED STUDY; CULTURE MEDIUM; ENZYME BINDING; GENE EXPRESSION; GENE OVEREXPRESSION; GENE TARGETING; GENETIC REGULATION; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN TARGETING; REAL TIME POLYMERASE CHAIN REACTION; RECEPTOR BLOCKING; SHAM PROCEDURE; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

EID: 84896816169     PISSN: None     EISSN: 21647860     Source Type: Journal    
DOI: 10.1089/biores.2012.9903     Document Type: Article

References (38)

1. Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277-300.
2. Chen CD, Welsbie DS, Tran C, et al. Molecular determinants of resistance to antiandrogen therapy. NatMed. 2004;10:33-39
3. Damber JE, Aus G. Prostate cancer. Lancet. 2008;371: 1710-1721.
4. Fusco A. MicroRNAs: a great challenge for the diagnosis and therapy of endocrine cancers. Endocr Relat Cancer. 2010; 17:E3-E4.
5. Negrini M, Nicoloso MS, Calin GA. MicroRNAs and cancer-new paradigms in molecular oncology. Curr Opin Cell Biol. 2009;21:470-479.
6. DeVere White RW, Vinall RL, Tepper CG, et al. MicroRNAs and their potential for translation in prostate cancer. Urol Oncol. 2009;27:307-311.
7. Czech MP. MicroRNAs as therapeutic targets. N Engl J Med. 2006;354:1194-1195.
8. Ribas J, Ni X, Haffner M, et al. miR-21: an androgen receptorregulated microRNA that promotes hormone-dependent and hormone-independent prostate cancer growth. Cancer Res. 2009;69:7165-7169.
9. Ribas J, Lupold SE. The transcriptional regulation of miR-21, its multiple transcripts, and their implication in prostate cancer. Cell Cycle. 2010;9:923-929.
10. Sun T, Wang Q, Balk S, et al. The role of microRNA-221 and microRNA-222 in androgen-independent prostate cancer cell lines. Cancer Res. 2009;69:3356-3363.
11. Porkka KP, Pfeiffer MJ, Waltering KK, et al. MicroRNA expression profiling in prostate cancer. Cancer Res. 2007;67: 6130-6155.
12. Shi XB, Xue L, Yang J, et al. An androgen-regulated miRNA suppresses Bak1 expression and induces androgen-independent growth of prostate cancer cells. Proc Natl Acad Sci U S A. 2007;104:19983-19988.
13. Mitchell PS, Parkin RK, Kroh EM, et al. Circulating micro-RNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A. 2008;105:10513-10518.
14. Ozen M, Creighton CJ, Ozdemir M, et al. Widespread deregulation of microRNA expression in human prostate cancer. Oncogene. 2008;27:1788-1793.
15. Liao G, Chen LY, Zhang A, et al. Regulation of androgen receptor activity by the nuclear receptor corepressor SMRT. J Biol Chem. 2003;278:5052-5061.
16. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 2001;25:402-408.
17. Coppola V, De Maria R, Bonci D. MicroRNAs and prostate cancer. Endocr Relat Cancer. 2010;17:F1-F17.
18. Gandellini P, Folini M, Zaffaroni N. Towards the definition of prostate cancer-related microRNAs: where are we now? Trends Mol Med. 2009;15:381-390.
19. Epis MR, Giles KM, Barker A, et al. miR-331-3p regulates ERBB-2 expression and androgen receptor signaling in prostate cancer. J Biol Chem. 2009;284:24696-24704.
20. Zaman MS, Chen Y, Deng G, et al. The functional significance of microRNA-145 in prostate cancer. Br J Cancer. 2010;103: 256-264.
21. Gibbings DJ, Ciaudo C, Erhardt M, et al. Multivesicular bodies associate with components of miRNA effector complexes and modulate miRNA activity. Nat Cell Biol. 2009;11:1143-1149.
22. Kosaka N, Iguchi H, Ochiya T. Circulating microRNA in body fluid: a new potential biomarker for cancer diagnosis and prognosis. Cancer Sci. 2010;101:2087-2092.
23. Kosaka N, Iguchi H, Yoshioka Y, et al. Secretory mechanisms and intercellular transfer of microRNAs in living cells. J Biol Chem. 2010;285:17442-17452.
24. Skog J, Wurdinger T, van Rijn S, et al. Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol. 2008;10:1470-1476.
25. Tsujiura M, Ichikawa D, Komatsu S, et al. Circulating micro-RNAs in plasma of patients with gastric cancers. Br J Cancer. 2010;102:1174-1179.
26. Hausler SF, Keller A, Chandran PA, et al. Whole bloodderived miRNA profiles as potential new tools for ovarian cancer screening. Br J Cancer. 2010;103:693-700.
27. Zhou M, Liu Z, Zhao Y, et al. MicroRNA-125b confers the resistance of breast cancer cells to paclitaxel through suppression of pro-apoptotic Bcl-2 antagonist killer 1 (Bak1) expression. J Biol Chem. 2010;285:21496-21507.
28. Lu S, Wang A, Dong Z. A novel synthetic compound that interrupts androgen receptor signaling in human prostate cancer cells. Mol Cancer Ther. 2007;6:2057-2064.
29. Burich RA, Holland WS, Vinall RL, et al. Genistein combined polysaccharide enhances activity of docetaxel, bicalutamide and Src kinase inhibition in androgen-dependent and independent prostate cancer cell lines. BJU Int. 2008;102: 1458-1466.
30. Colabufo NA, Pagliarulo V, Berardi F, et al. Bicalutamide failure in prostate cancer treatment: involvement of multi drug resistance proteins. Eur J Pharmacol. 2008;601:38-42.
31. Jiang L, Huang Q, Chang J, et al. MicroRNA HSA-miR-125a-5p induces apoptosis by activating p53 in lung cancer cells. Exp Lung Res. 2011;37:387-398.
32. Lin KY, Zhang XJ, Feng DD, et al. miR-125b, a target of CDX2, regulates cell differentiation through repression of the core binding factor in hematopoietic malignancies. J Biol Chem. 2011;286:38253-38263.
33. Burd CJ, Morey LM, Knudsen KE. Androgen receptor corepressors and prostate cancer. Endocr Relat Cancer. 2006;13: 979-994.
34. Berrevoets CA, Umar A, Trapman J, et al. Differential modulation of androgen receptor transcriptional activity by the nuclear receptor co-repressor (N-CoR). Biochem J. 2004;379: 731-738.
35. Shang Y, Myers M, Brown M. Formation of the androgen receptor transcription complex. Mol Cell. 2002;9:601-610.
36. Song LN, Coghlan M, Gelmann EP. Antiandrogen effects of mifepristone on coactivator and corepressor interactions with the androgen receptor. Mol Endocrinol. 2004;18:70-85.
37. Hodgson MC, Astapova I, Hollenberg AN, et al. Activity of androgen receptor antagonist bicalutamide in prostate cancer cells is independent of NCoR and SMRT corepressors. Cancer Res. 2007;67:8388-8395.
38. Yoon HG, Wong J. The corepressors silencing mediator of retinoid and thyroid hormone receptor and nuclear receptor corepressor are involved in agonist- and antagonistregulated transcription by androgen receptor. Mol Endocrinol. 2006;20:1048-1060.